Hong Kong, China MDACS Listing Basics: What Device Registration Really Means

1. Key takeaways

Hong Kong, China has no dedicated legislation regulating medical devices. What the market calls a medical device registration certificate for Hong Kong, China is, in official terms, a listing under the Medical Device Administrative Control System (MDACS), operated on a voluntary basis by the Medical Device Division (MDD) of the Department of Health since 26 November 2004. A listing is an administrative arrangement rather than a licence, and it produces no statutory market access effect of its own. Practice changed on 23 March 2026, when the Phase C procurement rules took effect: applicable devices that are not listed have since been excluded from Department of Health procurement. MDD normally completes assessment within 12 weeks of receiving all required documentary evidence, the government charges no fee, and a listing remains valid for 5 years.

Three distinctions decide how a manufacturer should plan. First, the voluntary character of MDACS and the mandatory character of procurement sit on separate legal layers, and confusing them leads to wrong conclusions about urgency. Second, a listing number is not a registration certificate, and the wrong term in a tender file creates avoidable credibility risk. Third, five-year validity turns a listing into a renewable status with a calendar obligation rather than a one-off certificate. The regime is light at entry and demanding in maintenance.

The GRZAN view. The 12-week assessment is seldom the bottleneck. Assembling evidence that MDD accepts at first reading is, and that work begins months before submission.

2. Legal basis

An administrative arrangement, not subsidiary legislation. MDACS rests on published guidance notes rather than on an ordinance, so its requirements bite through procurement, professional practice and reputation rather than through penalties. GN-01, the Guidance Notes on Overview of the Medical Device Administrative Control System, is the governing overview; the current version was updated and issued on 1 September 2026, with Chapter 3 setting out the scope and Chapter 5 the application and approval process. MDD also publishes a one-page overview of the listing process, uploaded on 8 October 2025, which addresses who may apply and how an application runs. The government position on the existing regime is recorded in the joint response of the Health Bureau and the Department of Health, press release P2024011500706 of 15 January 2024.

What the assessment actually examines. A listing file follows GN-02 for Class II, III and IV general medical devices, or GN-06 for Class B, C and D in vitro diagnostic devices. The technical core is either a certificate issued by a conformity assessment body (CAB) or a marketing approval granted in a reference jurisdiction. The 12 weeks run from receipt of the complete evidence package, so completeness at first submission is what protects the schedule. No fee applies at any stage, and the five-year term is counted from the listing date.

3. Expert insights

Voluntary and mandatory operate at different levels. MDACS itself is an administrative arrangement without penalties. The real constraint comes from three external chains: procurement, where Department of Health purchasing rules apply; use, where the code of practice for private healthcare facilities applies; and legislation, through the Hong Kong Centre for Medical Products Regulation (CMPR) and the device law that will follow. Treating these three chains as one thing with MDACS is where most manufacturers from the Chinese mainland first misjudge the Hong Kong, China market. Each chain has a different decision-maker, a different timetable and a different remedy.

The assessment is verification of existing evidence, not a full technical review. MDD does not run an independent scientific evaluation. It verifies evidence that already exists: a certificate from a CAB, or a marketing approval from a reference jurisdiction. The operational consequence is significant. A product already approved by the NMPA of the Chinese mainland, the US FDA, the European Union, Japan, Canada, Australia, Korea or Singapore faces a materially lower technical threshold, because the file can be built on that approval. Only a product with no reference approval has to travel the CAB route, and that route is slower and costlier in almost every case.

No fee does not mean no cost. Official documents state the fee position as entirely waived. Cost actually arises in three places: a local entity able to act as local responsible person, conformity assessment where the CAB route is used, and document preparation. This is a practical estimate rather than a published figure, and it varies with class and with how much of the technical file already exists in a reference jurisdiction format. The policy intent behind the waiver is to lower the friction of listing, widen the installed base of listed devices and lay a foundation for the eventual statutory regime. That intent is the key to reading where Hong Kong, China policy is heading.

Language discipline is a compliance issue, not a style issue. A file that speaks of a registration certificate invites a question the applicant cannot answer, because no such certificate exists in the official system. Using the listing number and the term MDACS listing consistently across internal documents, quotations and tender submissions prevents that question from arising at the worst moment.

4. Practical recommendations

• Unify terminology before reworking process. Adopt MDACS listing and Hong Kong medical device listing number (HKMD Listing Number) in every internal and tender document, and remove references to a registration number that has no counterpart in the official system.
• Work backwards from the target date. Where Department of Health procurement is in scope, the listing must be valid at the quotation or tender closing date. Allowing 12 weeks for assessment plus 2 weeks for acknowledgement and number allocation, the latest sensible submission point is about 14 weeks before closing, a practical estimate.
• Audit reference approvals first. Confirm whether the product already holds a marketing approval in any of the 8 recognised reference jurisdictions, then choose between the CAB route and the reference approval route on that finding rather than on habit.
• Keep a listing register. Record the listing number, a copy of the certificate and the expiry date in the corporate compliance register, so that renewal is triggered by a date rather than by a reminder from a distributor.
• Settle the local responsible person early. Eligibility to apply depends on a local manufacturer or a local responsible person appointed by the manufacturer, so entity status and business registration should be confirmed before any dossier work is commissioned.

5. Verification checklist

• □ Product screened with the MDD online tool on whether it is a medical device.
• □ Classification confirmed as Class II, III or IV general medical device, or Class B, C or D in vitro diagnostic device.
• □ Product confirmed as outside the exclusions in paragraph 3.2.1 of GN-01.
• □ Reference jurisdiction approvals inventoried for completeness, validity and mutual independence.
• □ Local responsible person confirmed in terms of legal status and business registration.
• □ Submission date calculated backwards from the procurement or use-side deadline.
• □ Items marked as a practical estimate confirmed in writing with MDD on telephone 3107 8484 or by email to mdd@dh.gov.hk.

Regulatory information verified as at 29 October 2026 against the official sources listed under legal basis; where those sources are updated, the latest published version prevails.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for Hong Kong, China. Our team manages Medical Device Administrative Control System (MDACS) listings, coordinates import licensing, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com